Beta Bionics Executive Sells Shares Under Pre-Arranged Plan
Mark Hopman, the Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), executed a sale of 275 common shares on June 4, 2026. The transaction, valued at $3,385, was conducted at a per-share price of $12.31. This sale follows the terms of a Rule 10b5-1 trading plan established on May 13, 2025. Post-transaction, Hopman retains a direct stake o…